Semiannual Report — FY2026 H1
What SEIKAGAKU CORPORATION reported for the period from 2026-04-01 to 2027-03-31.
Filed 2026-11-12View the original on EDINET
How much it says
48Typical
What moved here
8named for the first time
Its own wording
27terms
Which filing this is
36/ 36newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim consolidated accounting period, revenue was ¥18,219 million. This reflected a decline in overseas pharmaceuticals, while the LAL business and other operations increased. SI-6603 did not obtain approval following receipt of an FDA CRL, while SI-449 progressed to obtaining marketing approval for a medical device, determination of its reimbursement price and its scheduled insurance listing.
Komori's summary of this document, not the document's own words.48Typical
How much this filing saysA weighted roll-up of 10 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 37 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
45
Typical
27
Almost nothing
75
Very detailed
62
Detailed
68
Detailed
0
Almost nothing
13
Almost nothing
55
Typical
50
Typical
R&D spend33億円Money spent making new things.
Cash left over14億円Cash from the business, less what went into equipment.
Spent on equipment20億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.